Globe News Wire


Otonomy Provides Update on OTIVIDEX® and OTO-313 Programs

FDA’s review confirms use of Negative Binomial model for analysis of primary endpoint in ongoing OTIVIDEX Phase 3 trial in Ménière’s disease; results still expected in first quarter of 2021Company finalizing design of Phase 2 trial for OTO-313 in tinnitus and expects...

Pin It on Pinterest